Amanote Research
Register
Sign In
Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation
Current Oncology
- Canada
doi 10.3747/co.23.3042
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
October 26, 2016
Authors
T. Le
E.B. Kennedy
J. Dodge
L. Elit
Publisher
MultiMed Inc.
Related search
Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The Lancet Oncology
Oncology
Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications
Archives of Gynecology and Obstetrics
Medicine
Gynecology
Obstetrics
A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Journal of Ovarian Research
Gynecology
Oncology
Obstetrics
Pegylated Liposomal Doxorubicin for Platinum-Resistant or Refractory M�llerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube and Peritoneal Carcinoma): A Single-Institutional Experience
Oncology Letters
Cancer Research
Oncology
Primary Fallopian Tube Carcinoma
Journal of Evolution of medical and Dental Sciences
Are Guidelines for Monitoring Chronic Disease in Primary Care Evidence Based?
British Medical Journal
Medicine
Discharge to Primary Care for Survivorship Follow-Up: How Are Patients With Early-Stage Breast Cancer Faring?
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Follow-Up Care Strategies After Treatment for Breast Cancer
